Bevacizumab-induced chronic interstitial pneumonia during maintenance therapy in non-small cell lung cancer.

Abstract

Bevacizumab is a monoclonal antibody targeting the vascular endothelial growth factor receptor and a key drug for advanced non-small cell lung cancer. There are few reports describing bevacizumab-induced chronic interstitial pneumonia. A 62-year-old man with advanced non-small cell lung cancer was admitted to our hospital with dyspnea. He previously received four courses of carboplatin plus paclitaxel with bevacizumab combination therapy and thereafter received four courses of maintenance bevacizumab monotherapy. A chest-computed tomography scan on admission revealed diffuse ground glass opacity. He had not received any other drugs and did not have pneumonia. Thus, he was diagnosed with bevacizumab-induced chronic interstitial pneumonia and was treated with a high dose of corticosteroids. After steroid treatment, his dyspnea and radiological findings improved. This case report is the first description of bevacizumab-induced chronic interstitial pneumonia during maintenance therapy in a patient with non-small cell lung cancer.

• Authors: Yasuhito Sekimoto, Motoyasu Kato, Takehiko Shukuya, Ryo Koyama, Tetsutaro Nagaoka, Kazuhisa Takahashi
• Journal: Respirology case reports (Respirol Case Rep) Vol. 4 Issue 2 Pg. e00151 (Apr 2016) ISSN: 2051-3380 [Print] United States
• PMID: 27081491 (Publication Type: Case Reports)